Abstract
Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Volume: 11 Issue: 1
Author(s): Wei Wang
Affiliation:
Keywords: Cancer biomarker, glycomics, N-glycan, oligosaccharide, personalized medicine, public health pharmacogenomics.
Abstract: Glycosylation, linking the glycan chains to protein or lipid, is the most common and complex post-translational modifications of proteins. One of the important functions of glycoprotein is to maintain the ordered social life of each cell in multicellular organisms. Glycosylation is sensitive to the biochemical environment leading to the alteration of glycan chains under the physiological condition and specific diseases such as cancer. Cancer and other lethal diseases cannot be diagnosed at early stage due to classic biomarker’s low sensitivity and specificity. Recently, the development of glycan profiling technologies has offered great promises for understanding the complex glycan structures and has increased interest in applying this technology for cancer studies. In this regard, to identify the glycans as the potential biomarkers of cancer has become an important direction for clinical cancer diagnosis. This paper summarizes the current research on validating and developing of the glycans as new cancer biomarkers and the nascent field of glycomics
Export Options
About this article
Cite this article as:
Wang Wei, Validation and Development of N-glycan as Biomarker in Cancer Diagnosis, Current Pharmacogenomics and Personalized Medicine 2013; 11 (1) . https://dx.doi.org/10.2174/1875692111311010008
DOI https://dx.doi.org/10.2174/1875692111311010008 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Recent Advances in the New Generation Taxane Anticancer Agents
Medicinal Chemistry TWIST1 Gene: First Insights in Felis catus
Current Genomics Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation A Review of Light Sources and Enhanced Targeting for Photodynamic Therapy
Current Medicinal Chemistry An Integrative “Omics” Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma
Current Cancer Drug Targets N7-Substituted-5-aryl-pyrrolo[2,3-d]pyrimidines Represent a Versatile Class of Potent Inhibitors of the Tyrosine Kinase c-Src
Mini-Reviews in Medicinal Chemistry Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Current Issues on Epileptic Women
Current Pharmaceutical Design Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Acoustic Radiation Force Impulse (ARFI) Imaging: A Review
Current Medical Imaging Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets Imaging Virus-Associated Cancer
Current Pharmaceutical Design Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Plant Phenylpropanoids as Emerging Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering
Current Medicinal Chemistry